Post by Galenicum

Milestone Achieved! Galenicum has successfully launched generic Dalbavancin in both the EU and the US. We are proud to secure a highly anticipated Day 1 launch in the EU and to be among the very first to bring this critical generic to the US market. Dalbavancin is a long-acting IV antibiotic for skin infections (ABSSSI). Its single-dose capability reduces hospital stays and helps patients get home sooner. "Our team has worked tirelessly to be first to market in the EU and among the earliest in the US," says Josep Vilanova Masdemont, Chief Commercial Officer of Galenicum B2B. "We’ve invested heavily to expand globally and optimize our scale, ensuring Galenicum remains an economically sustainable, reliable partner to healthcare systems well into the future." Congratulations to the entire team! #Galenicum #Pharma #Generics #Dalbavancin #HealthcareInnovation #GlobalSupply https://lnkd.in/eftZw-XB